Recent Updates
Recently added Catalysts

Privosegtor

Phase 3

Optic Neuritis | Small molecule | Neurology |Oculis Holding AG|Last Updated: Jun 3, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment210

FDA Designations

BREAKTHROUGH_THERAPYORPHAN_DRUGPRIORITY_REVIEW

Clinical trial landscape

Privosegtor · 1 trial · 1 indication

Phase 3 1
NCT07623668Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation ResearchOptic Neuritis
RECRUITING210 Analytics
PHASE3RECRUITING
Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
Optic Neuritis
NCT07623668210
Unlock trial analytics

Study Endpoints

Primary Endpoints

Proportion of participants achieving at least 15-letter gain from baseline in low contrast visual acuity (LCVA).
3 months

Secondary Endpoints

Proportion of participants achieving at least 30-letter gain from baseline in LCVA.
3 months
Mean change from baseline in LCVA.
3 months
Mean change from baseline in the ganglion cell - inner plexiform layer (GCIPL) thickness.
3 months
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
PrivosegtorEXPERIMENTAL -
PlaceboPLACEBO_COMPARATOR -

Interventions

NameTypeDescription
PrivosegtorDRUGPrivosegtor (OCS-05) 3 mg/kg/day IV for 5 treatment days
MethylprednisoloneDRUGMethylprednisolone 1 g/day IV for 5 treatment days
PlaceboOTHER0.9% sodium chloride (NaCl) solution IV for 5 treatment days
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 50 Years
SexALL
Healthy VolunteersNo
Study Sites1

Key Inclusion Criteria: * Adult men and women (aged 18 to 50 years) with the first episode of ON in the study eye, associated with unilateral visual loss. * Onset of visual loss symptoms in the previous 12 days before first administration of study treatment. Key Exclusion Criteria: \- Have a hist...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about Privosegtor

What is Privosegtor used for?

Privosegtor is an investigational small molecule being developed for the treatment of optic neuritis, a condition involving inflammation of the optic nerve. It is currently in Phase 3 clinical development and has not yet been approved by regulatory authorities.

Who makes Privosegtor?

Privosegtor is being developed by Oculis Holding AG, a biopharmaceutical company listed on the stock exchange under the ticker symbol OCS. The company is conducting a Phase 3 clinical trial of the drug in the United States.

What phase is Privosegtor in?

Privosegtor is currently in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA. The drug has received Breakthrough Therapy, Orphan Drug, and Priority Review designations from the FDA.

What clinical trials is Privosegtor in?

Privosegtor is being evaluated in a Phase 3 clinical trial with the identifier NCT07623668, titled 'Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research.' This randomized, double-blind, placebo-controlled trial is recruiting 210 participants with optic neuritis in the United States.

How does Privosegtor work?

The specific molecular target of Privosegtor has not been disclosed in available information. The drug is a small molecule being studied for its potential to treat optic neuritis, but its mechanism of action has not been publicly detailed.